Inovio Pharmaceuticals (INO) COVID Vaccine P1 Data Fails to Impress - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan reiterated a Neutral rating and $15.00 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
